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ANTIMICROBIAL SUSCEPTIBLIITY FOR STAPHYLO-
COCCUS SPP. ISOLATED FROM BLOOD IN ADULT PA-
TIENTS WITH HEMATOLOGICAL MALIGNANCES BE-
TWEEN 1990—2003
Bagirova N, Dmitrieva N; Memorial N.N. Blokhin
Cancer Research Center RAMS, Moscow, Russia
PURPOSE: to evaluate the changes of antimicrobial
susceptibility Staphylococcus spp. strains isolated
from blood of adult patients with hematological ma-
lignancies between 1990—2003.
RESULTS: Total 479 strains were obtained from
blood during 14 years, including 243 strains (50.7%)
of Staphylococcus spp.: S. aureus −10.4% (50/479),
coagulase-negative staphylococci (CNS) −40.3%
(193/479). We have not had any staphylococcus
strain resistant to vancomycin during the last 14
years. We have not had statistically signiﬁcant
differences between CNS and S. aureus strains in
resistance to all antimicrobial agents except for
clindamycin. S. aureus susceptibility to vancomycin
was 100%, to oxacillin −78%, to cefazolin −60%,
to ceftazidime −46%, to cefepime −48.6%, to
ciproﬂoxacin −64%, to gentamycin −62%, to clin-
damycin −66%. CNS susceptibility to vancomycin
was 100%, to oxacillin−65.8%, to cefazolin−49.7%,
to ceftazidime −46.1%, to cefepime −54%, to
ciproﬂoxacin −49.3%, to gentamycin −47.3%, to
clindamycin −49%. 7.5% (12/159) of S. aureus
strains were isolated from blood at the 1st period of
time (1990—1996) and 11.9% (38/320) of S. aureus
strains were isolated from blood at the 2nd period
of time (1997—2003). There were no signiﬁcant
differences in frequency of S. aureus isolation. 34%
(54/159) of CNS strains were isolated from blood
at the 1st period of time (1990—1996) and 43.4%
(139/320) of CNS strains were isolated from blood
at the 2nd period of time (1997—2003). There are
signiﬁcant changes in frequency of isolation CNS
(p < 0.05).Meticillin-resistant S. aureus (MRSA)
represented 22% (11/50), and meticillin-resistant
CNS (MR-CNS) presently account for over 34.2%
(66/193).
CONCLUSION: The results of this trial demonstrate
that gram (+) cocci (mainly coagulase-negative
staphylococci) were predominant isolates from
blood. All Staphylococcus spp. strains were suscep-
tible to vancomycin. There are signiﬁcant changes
in frequency of isolation CNS (p < 0.05) last years.
MRSA from blood represented 22%, and MR-CNS
−34.2%.
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CMV PNEUMONIA IN PATIENTS WITH LYMPHOMA
Chemaly RF*, Torres H, Hachem RY, Raad II, Younes
A, Luna M, Rodriguez G, Aguilera E; Department of
Infectious Diseases, Infection Control and Employee
Health, The University of Texas M.D. Anderson Can-
cer Center, Houston, TX
OBJECTIVE: Despite antiviral therapy, CMV pneu-
monia (CMVp) is associated with high morbidity and
mortality in immunocompromised patients. With
the use of more immunosuppressive regimens, pa-
tients with lymphoproliferative disorders are at
increased risk for CMV reactivation and disease.
We describe our experience at UT-MDACC for CMVp
in patients with lymphoma.
METHODS: We reviewed the records of patients
with lymphoma and CMVp who were evaluated at
UT-MDACC between 1997 and 2003. We describe
the incidence, characteristics, treatment, and out-
come of CMVp in these patients. Patients with ei-
ther bone marrow transplantation or HIV infection
were excluded.
RESULTS: Twenty-eight patients with lymphoma
with a total of 33 episodes of CMVp were iden-
tiﬁed. The incidence of CMVp from 1997 to 2002
increased by 5-fold (3 vs 15/1000 admissions;
P < 0.05). Most episodes occurred in patients who
have non-Hodgkins lymphoma (88%) with active
(85%), advanced stage III—IV (92%) or relapsed dis-
ease (53%). In 13 episodes (33%), patients were
admitted to ICU; 7 of them (54%) required mechan-
ical ventilation. All patients had received prior
chemotherapy (salvage regimen in 64%), and most
(82%) had received high dose corticosteroids within
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180 days before the onset of CMVp. All patients
were symptomatic at the time of diagnosis, mainly
with fever (81%), cough (70%) and dyspnea (55%).
Most of the patients (82%) had bilateral inﬁltrates
on presentation. Lymphopenia was observed in only
11 (35%) of 31 episodes. Interestingly, concomitant
CMV viremia was detected in only 9 of the 24 (38%)
episodes where CMV antigenemia was done. The
yield for CMV in bronchoalveolar lavage (BAL) was
signiﬁcantly higher by culture (shell vial assay 75%;
conventional culture, 62%) versus cytology (8%) or
immunohistochemistry stain (0%) [P < 0.01]. An-
tivirals for CMVp were given in combination in only
2 patients. CMV-attributed mortality was 26% (7 out
27 patients with outcome data). Predictors of poor
outcome included use of mechanical ventilation
(P = 0.02), development of toxicity to antivirals
(P = 0.05), and relapse of CMVp [3/4 patients with
at least one relapse of their infection died vs 3/24
with no relapse (P = 0.01)].
CONCLUSIONS: The incidence of CMVp is on the
rise in patients with lymphoma. No correlation
was found between positive CMV antigenemia and
CMVp. CMV detection in BAL was much higher with
culture methods. Combination of antivirals may
be of beneﬁt, particularly in patients with initial
relapse of CMV disease and/or on mechanical ven-
tilation. The beneﬁt of CMV pre-emptive or pro-
phylactic strategies for high-risk patients need to
be determined in future studies.
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RISK ASSESSMENT IN HEMATOLOGICAL MALIGNAN-
CIES PATIENTS WITH FEVER AND PULMONARY IN-
FILTRATES: A HISTORICAL COHORT STUDY
Ofﬁdani M*, Corvatta L, Malerba L, Marconi M,
Bichisecchi E, Cecchini S, Manso E, Principi T,
Gasparini S, Leoni P; Department of Medicine, Im-
munology and Haematology, Department of Radi-
ology, Department of Microbiology, Intensive Care
Unit, Division of Pneumology, University of Ancona
and Azienda Ospedali Riuniti of Ancona, Ancona,
Italy
Mortality rate of fever associated with pulmonary
inﬁltrates after chemotherapy for haematological
malignancies remains higher than that reported for
febrile neutropenia without pneumonia. Neverthe-
less, few studies have been addressed to identify
risk factors predicting the outcome of pneumonia
in this group of patients and many of these took
into account clinical features occurred during the
episode or assessable only retrospectively. The pur-
pose of this study was to assess factors, available
until the onset of fever and pulmonary inﬁltrates,
affecting the outcome of pneumonia and, combin-
ing them, to build a risk model that could affect
clinical decisions making in this ﬁeld. A historical
cohort of 110 patients affected by haematological
malignancies with fever and pulmonary inﬁltrates
were studied. The main end-points of the study
were the descriptive analysis of the clinical char-
acteristics, the epidemiology and the outcome of
episodes of fever with pulmonary inﬁltrates and
the identiﬁcation of factors affecting outcome,
with the ultimate goal to build a risk model for
outcome. Using parameters available at the onset
of pneumonia, univariate and multivariate analyses
were performed to assess factors affecting out-
come. After one point was assigned to signiﬁcant
variables, a score of prediction was calculated for
each patient with the goal to build a scoring sys-
tem predicting patients at low risk of death from
pneumonia. Median age of 110 studied patients was
54 years (range 20—75) and 56 (51%) were male.
Fifty-one patients (46%) had acute myeloid (AML)
and 20 (18%) acute lymphoblastic leukemia; 29 pa-
tients (27%) had non-Hodgkins lymphoma (NHL), 5
(4.5%) multiple myeloma (MM) and 5 (4.5%) blast
crisis of chronic myeloid leukemia. Most pneu-
monia was caused by bacteria (74.5%), especially
Gram negative micro-organisms, whereas fungi
were isolated in 7 patients (13.7%). Viral pneu-
monia were documented in 6 cases, all caused by
Cytomegalovirus. The main radiological patterns of
pulmonary inﬁltrates were: consolidations (71%),
interstitial (44%), ground-glass (36%) and nodular
(27%). Empiric antibiotic therapy was successful
in only 7 patients (6%). The remaining patients
needed to modify antibiotics (86%) and/or to add
antifungal (60%) or antiviral (17%) therapy. Overall,
the response was achieved in 79 patients (72%).
Crude mortality from fever with pulmonary inﬁl-
trates was 23% (25 patients) and probability of
survival at 90 days was 79%. Univaraiate analysis
found that favourable outcome was statistically
associated with age >60, sex male, complete re-
mission obtained before the current chemotherapy,
phase of therapy other than induction, no previous
infections, favorable trend in WBC count, anti-
fungal prophylaxis, CRP >10mg/dl, albumin level
3 g/dl and immunoglobulin 0.4 g/dl. In multivariate
analysis factors associated with cure from pneu-
monia were favourable trend in white blood cell
count (OR = 5.6; CI95% = 1.7—18.9; p = 0.001),
C-reactive protein <10mg/dl (OR = 4.6; CI95%
= 1.6—13.8; p = 0.001) and serum albumin >3 g/dl
(OR = 3.2; CI95% = 1.4—7.3; p = 0.004). Low-risk
(score 2—3) and high-risk patients (score 0—1) had a
survival of 95% and 46%, respectively (p < 0.0001).
The model showed a speciﬁcity of 88% and a pre-
dictive positive value of 95%. ROC curve showed
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that discriminatory power of the model was 80%
(CI 70—90%). This risk model accurately pre-
dicts patients with haematological malignancies
surviving from pneumonia and, once prospec-
tively validated, it might be used to select pa-
tients for testing new diagnostic and therapeutic
strategies.
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PROSPECTIVE OBSERVATIONAL EVALUATION OF
AMPHOTERICIN B FORMULATIONS IN EUROPEAN
HEMATOLOGY/ONCOLOGY PATIENTS
Ullmann AJ*1, Sanz Alonso M2, Tramarin A3, Barnes
R4, Wu K5, Gerlach B6, Krobot K6; 1Klinikum Jo-
hannes Gutenberg University Mainz, Germany;
2Hospital Universitario La Fe, Spain; 3Ospedale
Civile San Bortolo, Italy; 4Christie Hospital, United
Kingdom; 5St. John’s University, USA; 6MSD Sharp &
Dohme GmbH, Germany; Gerth WC, Merck & Co.,
Inc., Outcomes Research, USA; on behalf of the
LEAD I Investigators
BACKGROUND: Amphotericin B (AmB) has been
the standard therapy for most invasive fun-
gal infections but is associated with signiﬁcant
adverse events (AEs) including nephrotoxicity
(NT). Liposomal and other lipid-based formu-
lations have been developed to diminish these
toxicities.
OBJECTIVE: This study aims to assess the incidence
of NT, mortality, and hospital length of stay (HLOS)
associated with AmB treatment.
METHOD: A prospective observational study was
conducted from December 2000 to September
2001 to collect outcomes data on adult hema-
tology/oncology patients consecutively treated
with AmB at 19 hospitals in Europe (Germany,
Italy, Spain and United Kingdom). NT was de-
ﬁned as a 50% increase of serum creatinine (SCr)
from baseline. Multiple logistic regressions were
used to predict the incidence of NT and hos-
pital mortality, and a Cox proportional hazards
model was developed to assess the inﬂuence of
NT on HLOS, while controlling for covariates (e.g.,
underlying medical condition, type of infection
treated).
RESULTS: A total of 418 patients primarily with
leukemia or lymphoma and treated with AmB pri-
marily for possible or suspected invasive fungal in-
fections were evaluated. Initial AmB formulations
were deoxycholate (AmBd), liposomal (AmBisome,
L-AmB), and other lipid formulations (Abelcet,
ABLC & Amphotec, ABCD) in 62%, 27%, and 11% of
patients, respectively. More than half (55%) of pa-
tients had a 50% increase in SCr after receiving AmB
(66% AmBd, 29% L-AmB, 55% ABLC/ABCD). In pa-
tients whose initial treatment was AmB, 36% were
switched to L-AmB/ABLC/ABCD primarily because
of increased SCr (45.7%) or other AmB attributed
AEs (41.3%). Observed clinical response to treat-
ment was complete/partial, failed, and indetermi-
nant in 54%, 24%, and 22% of patients, respectively.
In the 390 patients with normal kidney function at
AmB initiation, 221 patients (57%) developed NT.
Predictors of NT included formulation type (AmBd
> ABLC/ABCD > L-AmB) and duration of treat-
ment. Among patients developing NT: 52 > (24%)
died vs 30 (18%) in non-NT patients; mean HLOS was
27.0 days vs 21.7 days in non-NT patients. Multiple
logistic regression analysis revealed that severe NT
(200% increase in SCr) was a signiﬁcant predictor
for mortality [OR = 6.2, p < 0.001]; as were severe
underlying medical conditions [OR = 1.8 p = 0.05]
and documented infection [OR = 2.1, p = 0.01].
NT was associated with HLOS in Cox proportional
hazards analyses censored at death [hazard ratio
of hospital discharge 0.68; median HLOS: 26 vs. 20
days, p = 0.001].
CONCLUSIONS: The study re-afﬁrms that polyene
antifungals have a high potential for NT. In pa-
tients with normal kidney function NT is associ-
ated with signiﬁcant increases in hospital length of
stay and mortality. Newer less toxic IV antifungals
have the potential to reduce the burden of excess
hospital days and mortality associated with AmB
toxicities.
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POPULATION PHARMACOKINETICS OF CEFEPIME IN
FEBRILE NEUTROPENIC PATIENTS
Lee DG*, Choi SM, Yim DS1, Shin WS; Departments
of Internal Medicine & Pharmacology1, College of
Medicine, The Catholic University of Korea, Seoul,
Korea
OBJECTIVE: Cefepime is a broad spectrum cephalo-
sporin that is used for various pathogens includ-
ing Pseudomonas aeruginosa. Its dosing regimen in
Korea has been conﬁned to 2 g q 12 h due to the
reimbursement guidelines set for budget contain-
ment policy. To ﬁnd out scientiﬁc guideline for ce-
fepime dosing regimen in Korean patients, knowl-
edge on its population pharmacokinetics is a useful
reference.
METHODS: We recruited 51 febrile neutropenic pa-
tients with hematologic malignancy. For the control
of their infections, cefepime was given together
with other antibiotics. Peak (1—3h after dosing) and
trough (around 6 h after dosing) blood samples per
patients were taken for the mixed effect model-
ing analysis using NONMEM Ver. V. Simulation based
upon the population parameters was performed and
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500 patients data made up thereafter were tested
for the time over MIC 2, 4, 8mg/L.
RESULTS: CL was proportional to CLcr, but Vd was
not explained by any of the covariates. At the MIC
of 2mg/L, TOM was greater than 40% dosing in-
terval in all simulated patients. At the MIC of 4
and 8mg/L, 92% and 67% of the simulated patients
had TOM greater than 40% of dosing interval respe-
ctively.
CONCLUSIONS: The present study is the ﬁrst re-
port of population pharmacokinetics of cefepime in
febrile neutropenic patients. We expect that this
result will be used as a fundamental data for the ra-
tional pharmacotherapy of high-cost antibiotics in
Korea.
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INVASIVE FUNGAL INFECTIONS AMONG PEDIATRIC
PATIENTS WITH HEMATOLOGIC MALIGNANCIES AT
KFSH & RC/KFCCC & R, JUNE 1998—MARCH 2003
Al Mohsen I*, Al Kordy F, Serhan R, Al Ahmari A,
Belgaumi A, Chaundry A. Joy, L, Al Jumaah S, Al
Hajjar S, ElSolh H; King Faisal Specialist Hospital &
Research Centre, Riyadh, Saudi Arabia
OBJECTIVES: To deﬁne the magnitude of the prob-
lem, study factors associated with increased risk of
invasive fungal infections (IFI) and outcome.
METHODS: From June 1998 to March 2003, all
radiological studies of patients with hemato-
logic/oncologic disorders were evaluated for in-
clusion. All cases of invasive fungal infection were
reviewed. The criteria for inclusion were obvi-
ous lesion suggestive of fungal infection shown on
radiological studies, and fungal infections were
classiﬁed as ‘‘proven’’, ‘‘probable’’, ‘‘possible’’
or ‘‘insufﬁcient evidence’’ according to a prior
deﬁnitions.
RESULTS: A total of 1615 patient charts were re-
viewed. The underlying diagnoses include ALL
410, SCT 293, AML 133, non-malignant hematol-
ogy 288, NHL/solid tumuors 491. 152 (9%) had
evidence of fungal infection (55 [36%] ‘deﬁnite
= proven/probable’, 97 [64%] ‘possible’). Biopsy
was performed in 94 cases and the ﬁndings in-
cluded budding yeast in 10 patients, septated hy-
phae in 19, and hyphae with no speciﬁcations in
12 patients. Delays in performing diagnostic pro-
cedures possibly resulted in the lower incidence
of ’deﬁnite’ IFI (36% vs 64% ‘‘possible’’). The
overall incidence of fungal infection was 9%, be-
ing highest for AML (39%), followed by ALL (17%).
The majority of IFI developed during or immedi-
ately after induction (42% of IFI in AML and 53%
of IFI in ALL), which can be a target for interven-
tion. The infections included disseminated fun-
gal infection (36%), CDC (11%), pulmonary fungal
infection (43%) and aspergillosis (9.5%) includ-
ing pulmonary, Para nasal sinuses, skin and dis-
seminated. IFI was radiogically diagnosed during
neutropenia in 123 patients (81%). Ten patients
died due to fungal infection (7%), 75 (49%) were
cured, 26 (17%) were alive with fungal infection,
and 39 patients (26%) died due to primary disease
seemingly unrelated to fungal infection. Mortal-
ity due to IFI in this study is less than what is
reported in the literature and could be a result
of our practice of early intervention. The aver-
age LOS for IFI was 56 days compared with the
usual 12 days, which can add to the increased
cost.
CONCLUSIONS: Invasive fungal infection is becom-
ing a serious problem. Furthermore, acute invasive
fungal infection is associated with a much higher
mortality. Early diagnosis with prompt antifungal
therapy, or even with surgical intervention, might
be warranted to save patients’ lives.
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THE IMPACT OF STOOL SURVEILLANCE (SS) IN PA-
TIENTS WITH HEMATOLOGIC MALIGNANCIES (HM)
ON CONTROLLING OUTBREAK OF VANCOMYCIN
RESISTANT ENTEROCOCCAL (VRE) BACTEREMIAS
Hachem R*, Graviss L, Hanna H, Arbuckle R, Dvo-
rak T, Chemaly R, Perego C, Tarrand J, Raad I; The
University of Texas M.D. Anderson Cancer Center,
Houston, TX
BACKGROUND: HM patients (pts) are frequently col-
onized with VRE and undergo prolonged hospital-
ization associated with long periods of neutrope-
nia. We showed that all HM pts with VRE bacteremia
had prior stool colonization. These colonized pts
could become the source of spread of VRE in the
hospital.
OBJECTIVE: To determine the impact of SS of HM
pts in controlling the outbreak of VRE bacteremia.
METHODS: In 1997, a SS policy was initiated. All
hospitalized pts with HM had a stool culture on
admission and every week thereafter for a total
of 3 weeks. Any pt with a positive SS culture was
placed on contact isolation. The total amount of
vancomycin (VANC) used in a particular year was
determined in grams/103 pt-days. The incidence
density of VRE bacteremia was determined for a
particular year per 105 pt-days. All VRE isolates
causing bacteremia were tested by pulsed ﬁeld gel
electrophoresis (PFGE). Outbreak VRE bacteremias
were those that occurred in 2 or more pts during
the same year caused by a VRE strain that was in-
distinguishable by PFGE.
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RESULTS:
YR VANC grams/103
pt-days
Incidence Density per 105
pt-days
Total VRE
bacteremias
Outbreak VRE
bacteremias
1997 272 32 18
1998 213 35 9
1999 233 19 0
2000 283 12 0
2001 310 12 0
2002 324 13 0
2003 288 17 0
CONCLUSIONS: Despite a steady use of VANC, the
SS program in high-risk HM pts resulted in complete
control of outbreak VRE bacteremia at our institu-
tion.
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LABORATORY DIAGNOSIS OF RESPIRATORY VIRAL
INFECTIONS IN THE IMMUNOCOMPROMISED HOST
USING POLYMERASE CHAIN REACTION
Treffene S, Hawarami K, Goodman B, Breuer J,
Ushiro-Lumb I*, Jeffries D; Department of Virology,
St. Bartholomew’s Hospital, London
Viral pneumonia in immunocompromised patients
carries signiﬁcantmorbidity andmortality. Immuno-
compromised patients in our hospital undergo viro-
logical surveillance upon appearance of symptoms
of upper respiratory tract infection (URTI); they
are treated pre-emptively with Ribavirin if posi-
tive for Respiratory Syncytial Virus (RSV) or Parain-
ﬂuenza Virus 1, 2, or 3 (PF), and with Oseltamivir
or Zanamivir if positive for Inﬂuenza A (Flu A) or B
(Flu B) Virus.
OBJECTIVE: We have used immunoﬂuorescence (IF)
and Polymerase Chain Reaction (PCR) to study the
epidemiology of respiratory viral pathogens in our
immunocompromised patient population.
METHODS: Patients with haematological malig-
nancies or acquired, congenital or iatrogenic im-
munodeﬁciency were sampled (nasopharyngeal
aspirate, nasal wash or bronchoalveolar lavage)
if symptoms of URTI or LRTI were present. All
respiratory samples were initially tested for the
presence of RSV (A/B), Flu A, Flu B, PF 1/2/3
and Adenovirus (Ad) using an established indirect
IF method for viral antigen detection. Two mul-
tiplex PCR assays for the detection of the above
viruses and including an internal control (k-ras)
were introduced in winter 2003/4. All samples
testing negative by IF were then processed by
PCR.
RESULTS: See table below.
CONCLUSION: Our results demonstrate the signif-
icant increase in sensitivity of PCR in detecting
the presence of viruses in respiratory specimens.
We are currently transferring to a real-time plat-
form, which should support the management
of high-risk patients even further by facilitat-
ing the pre-emptive treatment with antivirals
and the monitoring of virological response to
treatment.
Adults (sample size 223) RSV FLU A FLU B Ad PF TOTAL
IF+ 19 8 0 3 27 57(25.5%)
IF−/PCR+ 9 4 0 0 11 24(10.8%)
Total Positive 28 12 0 3 38 81(36.3%)
Children (sample size 32) RSV FLU A FLU B Ad PF TOTAL
IF+ 3 10 0 0 0 13(40.6%)
IF−/PCR+ 2 1 0 0 0 3 (9.4%)
Total Positive 5 11 0 0 0 16 (50%)
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LOWER RESPIRATORY TRACT INFECTIONS IN NEU-
TROPENIC ARGENTINIAN CHILDREN WITH MALIG-
NANCIES
Devoto S, Rivas N, Hascalovici C, Teston L*, Sanchez
A, Cane A, Procopio A, López EL; Hospital de Niños
‘‘R. Gutiérrez’’ Buenos Aires, Argentina
The association of children with febrile neutropenia
(FN) and lower tract respiratory infections (LRTI) al-
ways represent a diagnostic challenge, particularly
in developing countries. Since few data are avail-
able in the literature, we sought to carry out this
study.
OBJECTIVE: The purpose was to identify conditions
and outcome of LRT I in our population.
METHODS: prospective study from October 1997 to
December 2002. We included all hospitalized FN
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children during this period. Data in relationshipwith
clinical, chest radiograph, CT scan, haematological
laboratory ﬁnding were reviewed. From them, LRTI
were analysed. Statistical analysis by Epi 6® was
done.
RESULTS: Episodes of FN were 518 in 276 patients.
Males predominated (61.6%), LRTI was seen in
79/597(13%). Median age in FN was 88.6month vs.
81.7 in LRTI p = NS. ALL in induction was the most
frequent underlying condition in both groups. Ab-
solute count of PMN showed no difference between
groups; almost the 70% had severe neutropenia (X
120). High risk (HR) patients represented 34% in
FN and 58% in LRTI p < 0.00008. Twenty ﬁve pa-
tients had no diagnosis of LRTI at admission and we
reached the diagnosis at 7.7 day, median 4± 8.59,
from them PMN increased in 6 days ±1.9. Most
frequent images were lobar 28 (35%), lobar and
interstitial inﬁltrated 16(20%) and interstitial 14
(18%). Sixteen (3%) HR-NF patients required ICU vs.
22 (37%) with LRTI p < 0.0005. LRTI group required
20.3 days of hospitalization and they needed 9 for
recovery of PMN vs. 9 and 6.3 for FN group, respec-
tively. Only the 27% of LRTI an agent was found.
Sepsis was present in 3.1% of FN vs. 13.9% in LRTI
group p < 0.0001.
CONCLUSION: Patients with LRTI required most days
of hospitalization and ICU than FN. The association
of sepsis and LRTI were signs of poor prognosis. Med-
ical efforts and economical supplies are necessary
to identify etiological causes.
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FATAL NOSOCOMIAL VARICELLA IN A CHILD WITH
ACUTE LYMPHOBLASTIC LEUKEMIA: UNSUCCESS-
FUL PROPHYLAXIS WITH ORAL ACYCLOVIR
Funakoshi Y, Okada M, Moriuchi M, Moriuchi H*; De-
partment of Pediatrics, Nagasaki University Hospi-
tal, Japan
BACKGROUND: In October 2003, promptly after di-
agnosis of an index case, control procedures were
initiated to prevent nosocomial varicella in the pe-
diatric ward.
METHODS: All immunocompetent inpatients who
were susceptible to varicella were vaccinated
within 72 h after exposure. All inpatients who were
highly immunocompromised were given either in-
travenous immunoglobulin within 96 h or oral acy-
clovir (ACV) (80mg/kg daily) for 7 days starting
from 7 days after exposure, irrelevantly to his-
tory of varicella or vaccination. Two weeks after
exposure, viremia was evaluated by real-time PCR.
RESULTS: A 4-year-old ALL patient, who had been
placed in isolation and had no contact with the in-
dex case, developed varicella on the 29th days, de-
spite chemoprophylaxis with oral ACV. Although skin
involvement was minimal and disappeared soon af-
ter administration of intravenous ACV, he died of
hepatic failure and DIC. While viremia was not de-
tected 2 weeks after exposure, high level of viremia
was detected even after disappearance of skin le-
sions.
CONCLUSIONS: Prophylaxis with oral ACV may fail
to prevent nosocomial varicella. High-risk patients
should be closely monitored over 4 wks, even if
hardly exposed.
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ORAL ANTIMICROBIAL PROPHYLAXIS IS NOT NEC-
ESSARY FOR BRIEF PERIODS OF NEUTROPENIA IN
PATIENTS RECEIVING CYCLICAL MYELOSUPPRES-
SIVE CHEMOTHERAPY
Morrison VA*; VA Medical Center, Minneapolis MN
INTRODUCTION: Oral prophylactic antimicrobial
agents have been used to prevent infection for pa-
tients with prolonged periods of neutropenia, such
as acute leukemia or stem cell transplant patients.
However, the utility of oral prophylaxis in patients
who have brief periods of neutropenia with admin-
istration of cyclical myelosuppressive therapy has
not been well-studied. We report interim results of
a prospective trial designed to address this issue.
OBJECTIVES: Determine the incidence of neu-
tropenic fever, number of neutropenic days, and
culture-documented infections in patients receiv-
ing oral antimicrobial prophylaxis compared to
placebo.
METHODS: Eligibility criteria were: age ≥18 years
(yrs); diagnosis of lymphoma, myeloma, small cell
lung cancer, or other solid tumors for which cycli-
cal myelosuppressive therapy was administered;
and demonstration by an initial cycle of myelosup-
pressive therapy that an absolute neutrophil count
(ANC) ≤500 cells/ml for a minimum of three con-
secutive days would result from the chemotherapy.
In a prospective, double-blind manner, patients
were randomized either to prophylaxis with oral
ciproﬂoxacin (500mg po bid) or placebo, beginning
on the day following chemotherapy and contin-
uing until either: the ANC was ≥500 cells/ml for
two consecutive days, fever of ≥100.5 ◦F with neu-
tropenia occurred; or a presumptive/documented
infection occurred.
RESULTS: At this interim analysis, 55 patients have
been enrolled on the study, and 46 are evaluable for
outcome. Patients’ age ranges from 49—80 (median
66) yrs; 44 are male. Diagnoses are non- Hodgkin’s
lymphoma (n = 16; 35%), small cell lung cancer
(n = 8; 18%), non-small cell lung cancer (n = 5;
11%), Hodgkin’s disease (n = 5; 11%), bladder can-
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cer (n = 3; 6%), and other solid tumors (n = 9; 19%).
Twenty-three pts were assigned to each treatment
arm. A total of 58 cycles of ciproﬂoxacin and 69 cy-
cles of placebo were administered. G-CSF was also
administered following some or all chemotherapy
cycles to 11 of 23 pts randomized to ciproﬂoxacin
(29 treatment cycles), and 12 of 23 pts receiving
placebo (32 treatment cycles). Six episodes of neu-
tropenic fever occurred in four pts over 127 cycles
of chemotherapy (5%). Three episodes were seen in
one pt on ciproﬂoxacin; Gram negative bacteremia
(Flavobacterium) was found in one episode, but no
source of infection was found in other two events.
The remaining three episodes of neutropenic fever
occurred in three pts randomized to placebo. No
source of infection was found in one case, one
pt developed dermatomal zoster, and the third pt
had a Pseudomonas aeruginosa urinary tract in-
fection. Toxicities were uncommon on both arms.
One pt assigned to ciproﬂoxacin discontinued the
study due to headaches related to the drug; a
placebo-assigned pt reported abdominal discom-
fort and diarrhea.
CONCLUSION: In this interim analysis, neutropenic
fevers and infections have been uncommon in
this patient population, whether randomized to
ciproﬂoxacin or placebo. Although the use of pro-
phylactic ciproﬂoxacin does not appear to impact
the incidence of infection/febrile neutropenia in
patients receiving cyclical myelosuppressive ther-
apy who have brief periods of neutropenia, formal
analysis of all study patients will be necessary to
make deﬁnitive conclusions.
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15-YEARS EXPERIENCE WITH INVASIVE PUL-
MONARY ASPERGILLOSIS (IPA) IN CHILDREN WITH
HEMATOLOGIC DISORDERS
Jabali Y, Mallatova N, Smrcka V*, Smrckova A, Timr
P; Regional Hospital, Ceske Budejovice, Czech Re-
public
OBJECTIVES: To review our experience in the di-
agnosis and management of IPA developing in chil-
dren undergoing intensive chemotherapy and/or
long-term immunosuppressive treatment over a
15-yr period.
METHODS: IPA cases occurring between 1.3.88 and
30.6.03 in children with a hematologic disorder
were reviewed and analyzed. The diagnosis was
based on clinical symptoms & signs, imaging studies
(CXR/CT) & standard mycological/serological tech-
niques. Management consisted of antifungals of
proven efﬁcacy against Aspergillus, and, if deemed
necessary, surgery. Survival data were updated to
29.2.04.
RESULTS: From 1988 to 2003, six cases of IPA were
diagnosed among 85 children treated for a hemato-
logic disorder. Four pts had acute lymphoblastic or
hybrid leukemia (3 relapsed), and one each refrac-
tory anemia with excess blasts in transformation or
severe hemophagocytic lymphohistiocytosis follow-
ing EBV infection. All had known risk factors lasting
a median of >3 to 5 wks, i.e. severe neutropenia,
use of steroids & antibiotics. Aspergillus fumigatus
was identiﬁed most commonly (in 5/6 pts). The di-
agnosis was considered proven in 3 cases, and prob-
able, suspected or possible in one case each. All
were managed with amphotericin B to a median to-
tal dose of 107.1mg/kg (range: 15.5—325.75) given
over a median of 41 days (range: 10—83). Three pts
received voriconazole for 66, 78 & 261 days as al-
ternative treatment or secondary prophylaxis. In 4
pts, itraconazole was used for primary prophylaxis,
follow-on/alternative therapy or secondary prophy-
laxis 17, 9, 12 days or long-term. Surgery performed
on 2 pts yielded a negative result. One boy died
of acute necrotizing pancreatitis possibly induced
by L-asparaginase, and one girl of disseminated as-
pergillosis. The infection was conﬁrmed at autopsy
in both. Resuming the scheduled therapy for the
underlying disease including 2 allogeneic stem-cell
grafts the remaining 4 pts are alive & well 100, 63,
11 & 10 months since the diagnosis of IPA.
CONCLUSIONS: Early diagnosis and aggressive anti-
fungal therapy can increase the cure rate of IPA,
thus setting the stage for providing curative treat-
ment for the underlying disorder and improving the
overall prognosis.
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ECTHYMA GANGRENOSUM CAUSED BY ASPERGIL-
LUS FLAVUS IN A FEBRILE NEUTROPENIC PATIENT
Chrysochoou S, Greka P*, Doufexis D, Vraila-Potamiti
D, Petrikkos PG, Daikos GL, Petrikkos GL; 1st De-
partment of Propedeutic Medicine, University of
Athens Medical School
We report the case of a 48 year-old male treated
with the NOVA-FLAG regimen for relapsed AM2L;
he remained neutropenic (PMNs < 50/l) until his
eventual death, 44 days post-chemotherapy. The
patient had also received combined treatment
with corticosteroids (prednisone 1.5mg/kg/d) and
gamma globulins (2 g/kg, total dose) between days
18 and 33 post-chemotherapy for hemophagocyto-
sis documented with bone marrow aspiration.
During his prolonged febrile neutropenia period, he
had been under several schemes with combinations
of extended spectrum antimicrobial chemotherapy
(both empirical and/or after microbiological docu-
mentation). The patient declined successive empir-
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ical antifungal treatments with either amphotericin
B (liposomal) or the newer azoles (itraconazole &
voriconazole) due to persistent side effects (rigors,
nausea and vomiting). He was therefore eventually
treated with ﬂuconazole (400mg bid, iv) with no
side-effects. Eight days later, a well demarcated
(3× 3 cm), painful erythematous lesion with evi-
dence of central necrosis was evident on the skin
overlying his left shoulder (ecthyma gangrenosum).
Scrapings from the central core of the lesion were
made available for both direct microscopic exam-
ination and cultures. The wet preparation of the
specimen (after treated with 10% KOH) was indica-
tive of an hyphomyces, whereas the corresponding
culture grew the typical Aspergillus ﬂavus colonies.
Ecthyma gangrenosum is a common manifesta-
tion of hematogenous spread of either microbial
pathogens (Pseudomonas aeruginosa, Aeromonas
hydrophila, Staphylococcus aureus) or fungi (Can-
dida spp., phaeoyphomycetes). Cases of fungemia
and subsequent erythema gangrenosum devel-
opment due to Aspergillus spp. have —to our
knowledge- only seldom been reported in the
literature but it is evident that they should al-
ways be kept in mind in the differential diag-
nosis of this entity in the immunocompromised
host.
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IDENTIFICATION OF FEBRILE NEUTROPENIC
ONCO-HAEMATOLOGICAL PEDIATRIC PATIENTS AT
LOW RISK OF COMPLICATION AND MORTALITY
THROUGH TALCOTT’S CRITERIA
Cesaro S*, Chinello P1, Pillon M, Cusinato R2,
Lionetto F1, D’Elia R1, Zanesco L; Paediatric
Haematology-Oncology Clinic, 1Service of Infec-
tious Diseases of Paediatric Immunocompromised
Host, 2Microbiology. Hospital of Padua (Italy)
OBJECTIVE: Recently, scores (Talcott, MASCC) have
been validated in the adults for the identiﬁcation
of low risk febrile neutropenic patients. These
patients may be discharged early from hospital
on oral antibiotic therapy following reduction
from i.v. antibiotics in hospital. We assessed the
Talcott’s score in pediatric onco-hamatological
patients.
METHODS: 241 febrile episodes that occurred in 117
neutropenic patients from 1996 to 1999 were retro-
spectively reviewed. Every episode was evaluated
for the presence of comorbidity factors at the on-
set of fever that required the hospitalization, e.g.:
hypotension, respiratory insufﬁciency, dehydration,
DIC, low platelet count, consciousness impairment,
pain, diarrhea, and for the status of patient’s un-
derlying malignancy.
RESULTS: According to Talcott’s criteria, the
episodes were classiﬁed into 4 groups. Group I:
febrile episode in hospitalized patient, 118;
Group II: febrile episode started at home, associ-
ated to comorbidity factors, 40; Group III: febrile
episode started at home, without comorbidity
factors but with relapsed or underlying disease
not well controlled, 26; Group IV: febrile episode
started at home, without comorbidity factors and
complete remission or well controlled underlying
malignancy, 57. The evaluation of the outcome
of the febrile episodes showed that the Talcott’s
group IV fared better with respect to: median
length of fever (days): I, 8; II, 4; III, 3.5; IV, 3;
(p < 0.0001); median length of antibiotic therapy
(days): I, 11; II, 7.5; III, 7; I, 6; (p < 0.0001); me-
dian duration of severe neutropenia (days): I, 11;
II, 6; III, 12; IV, 5.5; (p < 0.0001); response rate
to the empiric antibiotic therapy: I, 66%; II, 70%;
III, 65%; IV, 82%; (p 0.006); incidence of complica-
tions during the febrile episode: I, 21%; II, 12.5%;
III, 23%; IV, 0%; (p 0.0017); 15-day mortality: I,
5%; II, 2.5%; III, 15%; IV, 0%; (p 0.017). In multi-
variate analysis the use of antibiotic prophylaxis
and relapse of malignancy resulted in predictive
factors for occurrence of complications during
the febrile episodes; antifungal prophylaxis, re-
lapse and Talcott III group resulted predictive of
mortality.
CONCLUSIONS: Talcott-IV group allows identiﬁca-
tion of pediatric patients with fever and neutrope-
nia that are at low risk of complications and in-
fectious mortality. These ﬁndings, if conﬁrmed by
prospective trial, would allow one to reduce the
need for hospitalization and i.v. antibiotic therapy
in at least 10% of pediatric patients with fever and
neutropenia.
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FUNGAL STRAINS ISOLATED FROM CLINICAL SAM-
PLES OF HAEMATOLOGICAL PATIENTS
Swoboda-Kopec E1, Kawecki D1*, Wroblewska
M1, Sulik-Tyszka B1, Jedrzejczak W2, Luczak M1;
1Department of Medical Microbiology, Medical Uni-
versity of Warsaw, Warsaw, Poland; 2Department
of Haematology, Medical University of Warsaw,
Warsaw, Poland
AIMS: Analysis of the fungal strains cultured from
the clinical specimens taken from patients hospi-
talised in 2003 in the Department of Haematology,
Medical University of Warsaw and their susceptibil-
ity to antifungal agents using commonly in clinical
treatment.
METHODS: Fungal strains were cultured from the
following clinical specimens: stool, oral cavity, spu-
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tum, urine, blood, and other. Samples were inocu-
lated into Sabouraud’s medium. The isolates were
identiﬁed using Candi Select (Biorad) media and ID
32C and API Candida test (bioMerieux). The suscep-
tibility to antifungal agents was tested using E-test
(Biodisk).
RESULTS: In total 677 specimens were cultured
in 2003. Out of them 796 fungal strains were
isolated. Candida albicans was the most com-
monly isolated species 353- strains (44,3%), C.
glabrata 211- strains (26,5%), C. krusei 66- strains
(8,3%), Geotrihum spp. 50- strains (6,3%).All
strains of C. albicans were susceptible to am-
photericin B and ﬂuconazole, all strains of C.
glabrata were susceptible to amphotericin B and
itraconazole.
CONCLUSIONS: The most commonly isolates were
the strains of C. albicans, but clinical importance of
other Candida spp., such as C. glabrata, C. krusei
is emerging in haematological patients. Control of
nosocomial fungal infection in haematological pa-
tients is important in view of low susceptibility of
non-albicans Candida strains to commonly used an-
tifungal agents.
